CD34 and non-Hodgkin lymphoma: In a retrospective study conducted in Germany prior to the introduction of plerixafor, Wuchter et al found that NHL patients identified as poor mobilizers, all of those with CD34+ cell count between 11–19/μl (i.e., “borderline” poor mobilizers) collected sufficient hematopoietic stem cells (2.0 × 106 cells/kg).